AD Pipeline Watch: First Patients Dosed in New Phase 2b Trial of Zabalafin Hydrogel
Alphyn GmbH is initiating its CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in atopic dermatitis (AD) in Australia, and the first eight patients have been dosed, the Company reports.